Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
AUTOR(ES)
Murphy, B R
RESUMO
The fusion (F) glycoprotein of respiratory syncytial virus (RSV) induces neutralizing antibodies and antibodies that inhibit fusion of infected cells (FI antibody). It was previously shown that infants and children immunized with Formalin-inactivated RSV 20 years ago developed antibodies that bound to the F glycoprotein but were deficient in neutralizing activity. A reexamination of these sera indicated that they were also deficient in FI activity. Thus, Formalin-inactivated RSV vaccine stimulated an unbalanced immune response in which an unusually large proportion of the induced antibodies were directed against nonprotective epitopes rather than against the epitopes that induce functional antibodies, i.e., neutralizing and FI antibodies. This deficiency in stimulation of functional antibodies probably decreased the protective efficacy of the vaccine and could have contributed to potentiation of disease in the vaccines during subsequent RSV infection.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=266671Documentos Relacionados
- Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV
- Immunization of Macaques with Formalin-Inactivated Respiratory Syncytial Virus (RSV) Induces Interleukin-13-Associated Hypersensitivity to Subsequent RSV Infection
- Vβ14+ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV
- Enhancement of Respiratory Syncytial Virus Pulmonary Pathology in Cotton Rats by Prior Intramuscular Inoculation of Formalin-Inactivated Virus
- Formulation with CpG Oligodeoxynucleotides Prevents Induction of Pulmonary Immunopathology following Priming with Formalin-Inactivated or Commercial Killed Bovine Respiratory Syncytial Virus Vaccine